Enanta Pharmaceuticals, Inc. (ENTA)
NASDAQ: ENTA · Real-Time Price · USD
13.75
+0.30 (2.23%)
Jun 26, 2026, 3:02 PM EDT - Market open
Enanta Pharmaceuticals Employees
Enanta Pharmaceuticals had 120 employees as of September 30, 2025. The number of employees decreased by 11 or -8.40% compared to the previous year.
Employees
120
Change (1Y)
-11
Growth (1Y)
-8.40%
Revenue / Employee
$576,775
Profits / Employee
-$516,533
Market Cap
399.83M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 120 | -11 | -8.40% |
| Sep 30, 2024 | 131 | -14 | -9.66% |
| Sep 30, 2023 | 145 | -15 | -9.38% |
| Sep 30, 2022 | 160 | 5 | 3.23% |
| Sep 30, 2021 | 155 | 14 | 9.93% |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Puma Biotechnology | 179 |
| Adlai Nortye | 109 |
| Prelude Therapeutics | 79 |
| Century Therapeutics | 78 |
| Larimar Therapeutics | 71 |
| Lexeo Therapeutics | 59 |
| Eupraxia Pharmaceuticals | 49 |
| X4 Pharmaceuticals | 45 |
ENTA News
- 3 days ago - Enanta announces European Commission approval of Maviret - TheFly
- 3 days ago - Enanta Pharmaceuticals' Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus - Business Wire
- 8 days ago - Enanta to advance zelicapavir into registrational Phase 2b/3 clinical trial - TheFly
- 8 days ago - Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV) - Business Wire
- 22 days ago - Enanta Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 4 weeks ago - Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference - Business Wire
- 6 weeks ago - Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026 - Business Wire
- 6 weeks ago - Enanta Pharmaceuticals Earnings release: Q2 2026 - Filings